EMA starts review of GSK's monoclonal antibody to treat COVID-19 patients

The European Medicines Agency said on Thursday it is reviewing available data on the use of GlaxoSmithKline's monoclonal antibody to treat COVID-19 patients.

The agency said its review of VIR-7831 will include data from a study comparing its effect with that of a placebo in patients with mild to moderate COVID-19 who were at high risk of progressing to a more severe condition. (https://bit.ly/3n0spGx)

A more comprehensive rolling review is expected to start at a later time, the agency said.